Quinoline compounds as antiallergic and antithrombotic agents
Abstract
Abstract There are disclosed compounds of the formula <IMAGE> wherein X is <IMAGE> W is -O-, -S+13, <IMAGE> when n=0, or W is <IMAGE> when n=1, and the dotted line represents an optional double bond; Y is -CH2O-, -OCH2+13, -CH2S-, -SCH2+13, <IMAGE> n is 0-1; R1 is hydrogen, loweralkyl, loweralkoxy, lower alkanoyl, halo, trifluoromethyl, cyano or nitro; R2 is hydrogen or loweralkyl; R3 is loweralkyl, perfluoroloweralkyl or perfluorophenyl, with the proviso that when X=N, W=O or S and n=0, R3 is other than loweralkyl; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and in antithrombotic therapy.
Inventors
- 👤 John H. Musser
- 👤 Dennis M. Kubrak
- 👤 Anthony F. Kreft, III
Bibliographic Details
Claims Analysis
Total Claims: 5References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-22 | 1990-12-22 | 1991-06-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-22 | 1994-12-22 | 1995-06-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-22 | 1998-12-22 | 1999-06-23 | $7700.00 | Window Closed / Lapsed |